Gilead's expensive HIV prevention drug limits access for those who need it

A groundbreaking HIV prevention drug, lenacapavir, is facing access issues for many who need it most. Gilead Sciences priced the drug at $28,200 annually, offering limited doses at cost to low-income countries, with generic versions not expected until 2027. Despite taxpayer-funded research and high efficacy, Gilead's allocation plan and refusal to sell directly to organizations like Doctors Without Borders are criticized for delaying widespread access.